This Fallen Growth Stock Is Still a Wall Street Favorite: Here's Why
The stock may be down by 60% over the past 12 months, but Maravai LifeSciences Holdings (NASDAQ: MRVI) is still in Wall Street's good graces, with all 10 of the big-time financial analysts who cover the stock rating it as either a buy or a strong buy. In the face of such a steep decline, that's quite a strong endorsement of the company's potential.
Let's take a minute to see why Wall Street hasn't given up on this stock yet and to understand whether it might be a smart way to build more growth in your portfolio now.
Maravai's business model is to sell pure and ready-to-use nucleic acids to biopharma companies making molecular diagnostics and DNA- or RNA-based medicines. As you might have guessed, that means household-name companies making coronavirus vaccines based on nucleic acids -- like Moderna, Pfizer, and BioNTech -- are all potential customers. And that means the company is effectively selling shovels to players chasing the vaccine gold rush.
Source Fool.com
